// App-Quantinova.ai

157 : Removal Of Alpha/Beta+ T Cells and Of CD19+ B Cells From The Graft Translates Into Rapid Engraftment, Absence Of Visceral Graft-Versus-Host Disease and Low Transplant-Related Mortality In Children With Acute Leukemia Given HLA-Haploidentical Hematopoietic Stem Cell Transplantation

Researchers

Presenter

  • Alice Bertaina

Principal Investigators

  • Daniela Pende

  • Giuseppina Li Pira

  • Stefano Ceccarelli

  • Lavinia Grapulin

  • Giuseppe Palumbo

  • Maria Ester Bernardo

  • Simone Biagini

  • Francesca Moretta

  • Giuseppe M Milano

  • Irma Airoldi

  • Annemarie Moseley

  • Sergio Rutella

  • Alessandro Moretta

  • Lorenzo Moretta

  • Franco Locatelli

  • Michela Falco

  • Aurelie Bauquet

  • Benedetta Contoli

  • Barbarella Lucarelli

  • Letizia P. Brescia

  • Pietro Merli

  • Marco Andreani

Medical Centers

  • Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera Universitaria San Martino - Istituto Nazionale per la Ricerca sul Cancro,

  • International Center for Transplantation in Thalassemia and Sickle Cell Anemia. Mediterranean Institute of Hematology, Policlinic University of Roma Tor Vergata, Roma, Italy,

  • Department of Radiology and Radiotherapy,-Sapienz- University, Rome, Italy

  • University of Genoa, Genoa, Italy

  • Giannina Gaslini Institute, Genoa, Italy

  • Dipartimento di Medicina Interna, Universit di Genova, Genoa, Italy

  • Pediatric Hematology/Oncology, IRCCS Bambino Ges Childrens Hospital Rome, University of Pavia, Rome, Italy

  • Pediatric Hematology/Oncology and Transfusion Medicine, IRCCS Bambino Ges Childrens Hospital, Rome, Italy

  • University of Pavia, Pavia, Italy

  • Giannina Gaslini Institute, Laboratory of Oncology, Genoa, Italy

Locations

  • Italy

Companies

  • Bellicum Pharmaceuti

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lympho proliferative disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

  • Acute myelocytic leukemia

  • Cytomegalovirus infection

  • Acute Leukemia

Biomarkers

  • Natural Killer cells

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

  • Cluster of Differentiation 34

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved